The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline. DHA is a long chain omega-3 fatty acid (LC-PUFA) that plays an important role in neural and visual development and cardiovascular health.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
485
oral 900mg/day
Pivotal Research Center
Mesa, Arizona, United States
Pacific Research Network
San Diego, California, United States
Pacific Research Network
Vista, California, United States
Determine the effects of DHA, a nutritional supplement (900 mg/d) on improving cognitive functions (i.e. working memory, memory retention, attention, and executive function) in healthy elderly subjects at 24 weeks
Time frame: 24 weeks
Effects of DHA on visual acuity, levels of plasma phospholipids, and evaluating the safety and tolerability of the DHA dose administered
Time frame: 24 weeks
The study will include a screening period, baseline, and 24 week treatment period.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Radiant Research Denver
Denver, Colorado, United States
Bradenton Neurology
Bradenton, Florida, United States
Brain Matters Research
Delray Beach, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
Stedman Clinical Trials
Tampa, Florida, United States
Radiant Research Chicago
Chicago, Illinois, United States
Clinical Trial Center
Jenkintown, Pennsylvania, United States
...and 4 more locations